Multiple Myeloma Coverage from Every Angle

Second-Line Therapy for Myeloma: Adding Low-Dose Decitabine to Bortezomib

By: Kayci Reyer
Posted: Monday, July 6, 2020

According to findings from a single-center, open-label phase II Chinese study, published in the British Journal of Haematology, second-line treatment consisting of bortezomib, dexamethasone, and low-dose decitabine may prove to be safe and effective in patients with relapse or /refractory multiple myeloma. Baijun Fang, MD, of Zhengzhou University in China, and colleagues sought to determine whether decitabine might be a cost-effective, available-in-country addition to other antimyeloma agents.

The study included 47 patients with relapsed or refractory multiple myeloma who underwent up to eight cycles of bortezomib/dexamethasone/decitabine. Patients received 5 mg/m2 of intravenous decitabine on days 1 to 5; 1.3 mg/m2 of subcutaneous bortezomib on days 1, 4, 8, and 11; and 20 mg of oral dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12.

At the time of data cutoff on February 12, 2020, and at a median follow-up of 17.2 months, the overall response rate was 87%. A total of 15% of patients achieved a stringent complete response, 15% achieved a complete response, and 37% achieved a very good partial response. Among patients with bortezomib-refractory disease, the overall response rate was 75%, with 25% achieving at least a complete response and 62% reaching at least a very good partial response. The overall 12-month and 18-month progression-free survival rates were 72% and 67%, respectively, versus 50% and 50% for patients with bortezomib-refractory disease. The median progression-free survival for all groups was not reached.

Adverse events, the most common of which were peripheral neuropathy (43.5%), thrombocytopenia (41.3%), and fatigue (34.5%), were consistent with the established safety profile. Overall, three patients discontinued treatment due to grade 3 or 4 adverse events, and one patient did not complete the study due to early death.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.